Our client had developed a new diagnostic procedure with higher diagnostic sensitivity and specificity, but with higher direct medical costs compared to the gold standard. As a result, the method, due to its medical advantages, spread more slowly in the market than expected.
Based on health insurance company data, we conducted a cost-effectiveness analysis for our client, which showed that the new method saves follow-up costs by avoiding operations, i.e. it is the dominant alternative from a health-economic perspective. Based on this analysis, we also prepared a publication in collaboration with a clinical expert.
The cost-effectiveness analysis and health-economic publication helped our client to significantly increase the acceptance of his method with payers.